Previous 10 | Next 10 |
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the first quarter ended March 31, 2020. First Quarter Highlights Reported record revenues of $19.2 million in the first quarter of 2020 versus $14.1 million in the first...
Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the appointment Stephen Moore as General Counsel. “We are very pleased to welcome Stephen to the Personalis team. He has an impressive track record with more than 20 years of in-house legal e...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in three upcoming virtual investor conferences. Present at the Bank of America Securities 2020 Health Care Conference scheduled to be held virtually on Thu...
Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced the Accreditation Committee of the College of American Pathologists (CAP) has awarded re-accreditation to the Personalis Clinical Laboratory , Menlo Park, California based on results of a recent on-site...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its first quarter 2020 financial results after the market closes on Thursday, May 7, 2020. In conjunction with the release, the Company will host a conference call and webcast that day a...
HAMBURG, Germany and MENLO PARK, Calif. , April 21, 2020 /PRNewswire/ -- Indivumed GmbH ("Indivumed") and Personalis, Inc. (Nasdaq: PSNL) today announced that the two companies have entered into a collaboration in the field of personalized oncology. The partnership seeks to enable ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of their Pharma Research Solutions, the latest expansion of the company’s portfolio of comprehensive genomics assays and analytics. These solutions, which leverage Personalis’ p...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the 1-on-1 meetings at the upcoming 19th Annual Needham Virtual Healthcare Conference from Tuesday, April 14, 2020 through Wednesday, April 15, 2020. Abo...
Personalis ( PSNL ) has triggered my interest since it has gone public in the summer of 2019. With PSNL reporting its full-year results in the middle of the Corona crisis, it is time to update my stance on the company. Fourth-quarter results were more or less in line with expectations, and d...
News, Short Squeeze, Breakout and More Instantly...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tum...